Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial
Bruce L. Wilkoff,Giuseppe Boriani,Suneet Mittal,Jeanne E. Poole,Charles Kennergren,G. Ralph Corey,Andrew D. Krahn,Edward J. Schloss,Jose L. Gallastegui,Robert A. Pickett,Rudolph F. Evonich,Steven F. Roark,Denise M. Sorrentino,Darius P. Sholevar,Edmond M. Cronin,Brett J. Berman,David W. Riggio,Hafiza H. Khan,Marc T. Silver,Jack Collier,Zayd Eldadah,Reece Holbrook,Jeff D. Lande,Daniel R. Lexcen,Swathi Seshadri,Khaldoun G. Tarakji
DOI: https://doi.org/10.1161/CIRCEP.120.008503
2020-10-29
Abstract:Download figure Download PowerPoint In the WRAP-IT trial (Worldwide Randomized Antibiotic Envelope Infection Prevention), adjunctive use of an absorbable antibacterial envelope resulted in a 40% reduction of major cardiac implantable electronic device infection without increased risk of complication in 6983 patients undergoing cardiac implantable electronic device revision, replacement, upgrade, or initial cardiac resynchronization therapy defibrillator implant. There is limited information on the cost-effectiveness of this strategy. As a prespecified objective, we evaluated antibacterial envelope cost-effectiveness compared with standard-of-care infection prevention strategies in the US healthcare system. A decision tree model was used to compare costs and outcomes of antibacterial envelope (TYRX) use adjunctive to standard-of-care infection prevention versus standard-of-care alone over a lifelong time horizon. The analysis was performed from an integrated payer-provider network perspective. Infection rates, antibacterial envelope effectiveness, infection treatment costs and patterns, infection-related mortality, and utility estimates were obtained from the WRAP-IT trial. Life expectancy and long-term costs associated with device replacement, follow-up, and healthcare utilization were sourced from the literature. Costs and quality-adjusted life years were discounted at 3%. An upper willingness-to-pay threshold of 112 603/quality-adjusted life year. The incremental cost-effectiveness ratio remained lower than the willingness-to-pay threshold in 74% of iterations in the probabilistic sensitivity analysis and was most sensitive to the following model inputs: infection-related mortality, life expectancy, and infection cost. The absorbable antibacterial envelope was associated with a cost-effectiveness ratio below contemporary benchmarks in the WRAP-IT patient population, suggesting that the envelope provides value for the US healthcare system by reducing the incidence of cardiac implantable electronic device infection. URL: https://www.clinicaltrials.gov . Unique identifier: NCT02277990.